In our cervical cancer xenograft mouse model, co-administration of PTX with EGFR inhibitor erlotinib significantly prevented the tumor growth and relapse, which was associated with reduced expression of MUC1 and ABCB1, and diminished activity of EGFR. Here, EGFR is linked to neoplasm.